By a GenomeWeb Staff Reporter

NEW YORK (GenomeWeb News) – Aptiv Solutions today announced a partnership with Cancer Genetics for products and services directed at oncology clinical trials.

The two firms did not specify what products or services will result from the deal, but Aptiv said in a statement that they will provide "biopharmaceutical firms with a better understanding of modes of action of a variety of therapeutics and the role of biomarkers in the oncology drug development process."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: association between genome-wide homozygosity and traits like height and cognitive ability, improved CRISPR-Cas9 editing, and more.

A survey examines how age, political leanings, and more influence how Americans view certain scientific topics, the Associated Press reports.

A researcher who pleaded guilty to making false statements in research reports has been sentenced to four and a half years in prison and must pay $7.2 million back to the NIH.

The BabySeq project to study the risks and benefits of sequencing newborns is underway.